Compare TILE & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TILE | SLNO |
|---|---|---|
| Founded | 1973 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 1994 | 2014 |
| Metric | TILE | SLNO |
|---|---|---|
| Price | $28.08 | $39.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $36.00 | ★ $108.00 |
| AVG Volume (30 Days) | 398.6K | ★ 1.2M |
| Earning Date | 05-27-2026 | 05-29-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | 32.43 | ★ 108.90 |
| EPS | ★ 1.96 | 0.39 |
| Revenue | ★ $1,386,854,000.00 | $1,450,788.00 |
| Revenue This Year | $7.00 | $155.44 |
| Revenue Next Year | $5.46 | $57.99 |
| P/E Ratio | ★ $14.34 | $98.67 |
| Revenue Growth | 5.41 | ★ 138.82 |
| 52 Week Low | $17.31 | $32.63 |
| 52 Week High | $35.11 | $89.12 |
| Indicator | TILE | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 25.72 | 48.10 |
| Support Level | $27.55 | $38.17 |
| Resistance Level | $28.87 | $44.60 |
| Average True Range (ATR) | 1.06 | 2.28 |
| MACD | -0.63 | 0.20 |
| Stochastic Oscillator | 12.92 | 75.19 |
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.